163 related articles for article (PubMed ID: 38637634)
1. KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance.
Ash LJ; Busia-Bourdain O; Okpattah D; Kamel A; Liberchuk A; Wolfe AL
Curr Oncol; 2024 Apr; 31(4):2024-2046. PubMed ID: 38668053
[TBL] [Abstract][Full Text] [Related]
2. Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers.
Jiang J; Jiang L; Maldonato BJ; Wang Y; Holderfield M; Aronchik I; Winters IP; Salman Z; Blaj C; Menard M; Brodbeck J; Chen Z; Wei X; Rosen MJ; Gindin Y; Lee BJ; Evans JW; Chang S; Wang Z; Seamon KJ; Parsons D; Cregg J; Marquez A; Tomlinson ACA; Yano JK; Knox JE; Quintana E; Aguirre AJ; Arbour KC; Reed A; Gustafson WC; Gill AL; Koltun ES; Wildes D; Smith JAM; Wang Z; Singh M
Cancer Discov; 2024 Jun; 14(6):994-1017. PubMed ID: 38593348
[TBL] [Abstract][Full Text] [Related]
3. Progress in Targeting KRAS Directly.
Nissley DV; Stephen AG; Yi M; McCormick F
Methods Mol Biol; 2024; 2797():1-12. PubMed ID: 38570448
[TBL] [Abstract][Full Text] [Related]
4. Probing RAS Function Using Monobody and NanoBiT Technologies.
Whaby M; Nair RS; O'Bryan JP
Methods Mol Biol; 2024; 2797():211-225. PubMed ID: 38570462
[TBL] [Abstract][Full Text] [Related]
5.
Ceddia S; Landi L; Cappuzzo F
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012655
[No Abstract] [Full Text] [Related]
6. Targeting KRAS in cancer.
Singhal A; Li BT; O'Reilly EM
Nat Med; 2024 Apr; 30(4):969-983. PubMed ID: 38637634
[TBL] [Abstract][Full Text] [Related]
7. Clinical Acquired Resistance to KRAS
Tanaka N; Lin JJ; Li C; Ryan MB; Zhang J; Kiedrowski LA; Michel AG; Syed MU; Fella KA; Sakhi M; Baiev I; Juric D; Gainor JF; Klempner SJ; Lennerz JK; Siravegna G; Bar-Peled L; Hata AN; Heist RS; Corcoran RB
Cancer Discov; 2021 Aug; 11(8):1913-1922. PubMed ID: 33824136
[TBL] [Abstract][Full Text] [Related]
8. From bench to bedside: current development and emerging trend of KRAS-targeted therapy.
Chen Y; Liu QP; Xie H; Ding J
Acta Pharmacol Sin; 2024 Apr; 45(4):686-703. PubMed ID: 38049578
[TBL] [Abstract][Full Text] [Related]
9. Diverse alterations associated with resistance to KRAS(G12C) inhibition.
Zhao Y; Murciano-Goroff YR; Xue JY; Ang A; Lucas J; Mai TT; Da Cruz Paula AF; Saiki AY; Mohn D; Achanta P; Sisk AE; Arora KS; Roy RS; Kim D; Li C; Lim LP; Li M; Bahr A; Loomis BR; de Stanchina E; Reis-Filho JS; Weigelt B; Berger M; Riely G; Arbour KC; Lipford JR; Li BT; Lito P
Nature; 2021 Nov; 599(7886):679-683. PubMed ID: 34759319
[TBL] [Abstract][Full Text] [Related]
10. Acquired Resistance to KRAS
Awad MM; Liu S; Rybkin II; Arbour KC; Dilly J; Zhu VW; Johnson ML; Heist RS; Patil T; Riely GJ; Jacobson JO; Yang X; Persky NS; Root DE; Lowder KE; Feng H; Zhang SS; Haigis KM; Hung YP; Sholl LM; Wolpin BM; Wiese J; Christiansen J; Lee J; Schrock AB; Lim LP; Garg K; Li M; Engstrom LD; Waters L; Lawson JD; Olson P; Lito P; Ou SI; Christensen JG; Jänne PA; Aguirre AJ
N Engl J Med; 2021 Jun; 384(25):2382-2393. PubMed ID: 34161704
[TBL] [Abstract][Full Text] [Related]
11. KRAS Inhibitor Resistance in
Suzuki S; Yonesaka K; Teramura T; Takehara T; Kato R; Sakai H; Haratani K; Tanizaki J; Kawakami H; Hayashi H; Sakai K; Nishio K; Nakagawa K
Clin Cancer Res; 2021 Oct; 27(20):5697-5707. PubMed ID: 34365406
[TBL] [Abstract][Full Text] [Related]
12. Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial.
Pant S; Wainberg ZA; Weekes CD; Furqan M; Kasi PM; Devoe CE; Leal AD; Chung V; Basturk O; VanWyk H; Tavares AM; Seenappa LM; Perry JR; Kheoh T; McNeil LK; Welkowsky E; DeMuth PC; Haqq CM; O'Reilly EM
Nat Med; 2024 Feb; 30(2):531-542. PubMed ID: 38195752
[TBL] [Abstract][Full Text] [Related]
13. Liquid Biopsy Response Evaluation Criteria in Solid Tumors (LB-RECIST).
Gouda MA; Janku F; Wahida A; Buschhorn L; Schneeweiss A; Abdel Karim N; De Miguel Perez D; Del Re M; Russo A; Curigliano G; Rolfo C; Subbiah V
Ann Oncol; 2024 Mar; 35(3):267-275. PubMed ID: 38145866
[TBL] [Abstract][Full Text] [Related]
14. Combination Therapy and Appropriate Dosing to Target KRAS in Colorectal Cancer.
Yaeger R
N Engl J Med; 2023 Dec; 389(23):2197-2199. PubMed ID: 38055257
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
